Respiratory medicine
Windward Bio AG focuses on asthma, with clinical research centered on moderate and severe asthma in adult participants. The sponsor’s current work reflects interest in treatment areas where persistent airway inflammation and symptom control remain clinically important.
- Asthma
- Moderate asthma
- Severe asthma
The research landscape is concentrated in respiratory therapeutics, with active study sites across multiple countries and collaboration spanning several clinical centers.
Immunology and biologic response
Clinical activity includes evaluation of immunogenicity, indicating interest in immune responses relevant to biologic or targeted therapies used in chronic airway disease.
- Immunogenicity
- Immune-mediated response
- Biologic therapy assessment
This area supports research into how immune activity may influence treatment performance in asthma management.
Clinical pharmacology
The sponsor’s trial portfolio includes assessment of pharmacokinetics, reflecting attention to how investigational therapy is absorbed, distributed, and cleared in adults with respiratory disease.
- Pharmacokinetics
- Drug exposure
- Systemic disposition
These interests align with development work in targeted respiratory treatments and their behavior in clinical use.
Safety and tolerability
Windward Bio AG also studies safety, tolerability, and efficacy in the context of chronic airway disease, with attention to how investigational therapy is received by adults living with persistent asthma.
- Safety
- Tolerability
- Efficacy
The company’s activity is concentrated in a single respiratory program involving a network of 33 research sites across 5 countries.
